Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C12H18N6O3 |
| Molecular Weight | 294.3097 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C1=NC=NC2=C1N=CN2[C@@H]3O[C@H](CO)[C@@H](N)[C@H]3O
InChI
InChIKey=RYSMHWILUNYBFW-GRIPGOBMSA-N
InChI=1S/C12H18N6O3/c1-17(2)10-8-11(15-4-14-10)18(5-16-8)12-9(20)7(13)6(3-19)21-12/h4-7,9,12,19-20H,3,13H2,1-2H3/t6-,7-,9-,12-/m1/s1
| Molecular Formula | C12H18N6O3 |
| Molecular Weight | 294.3097 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28420111 | https://www.ncbi.nlm.nih.gov/pubmed/28528353
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28420111 | https://www.ncbi.nlm.nih.gov/pubmed/28528353
Puromycin aminonucleoside is a semi-synthetic derivative of puromycin lacking the methoxyphenylalanyl moiety. Puromycin aminonucleoside is the key intermediate in the synthesis of semi-synthetic analogues of puromycin. It does not inhibit protein synthesis or induce apoptosis but exhibits antitumor properties. Puromycin aminonucleoside-induced nephrosis is a well-described model of human idiopathic nephrotic syndrome, suppressing expression of integrin expression in cultured glomerular epithelial cells. Puromycin aminonucleoside is used to study human glomerular disease by inducing damage of murine glomerular podocytes and is used to study glomerular function and morphology.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| An ultrastructural study of the glomerular slit diaphragm in aminonucleoside nephrosis. | 1975 Nov |
|
| Activity of serum enzymes in puromycin aminonucleoside-induced nephrotic syndrome. | 1992 |
|
| Glomerular epithelial cell endocytosis in puromycin-induced glomerulopathy. | 1992 |
|
| Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis in rats. | 1992 Dec |
|
| The altered glomerular filtration slits seen in puromycin aminonucleoside nephrosis and protamine sulfate-treated rats contain the tight junction protein ZO-1. | 1992 Oct |
|
| Suppressed activities of cathepsins and metalloproteinases in the chronic model of puromycin aminonucleoside nephrosis. | 1999 |
|
| Effect of the in vivo catalase inhibition on aminonucleoside nephrosis. | 1999 Aug |
|
| Transient and sequential expression of chemokine mRNA in glomeruli in puromycin aminonucleoside nephrosis. | 2000 Jul |
|
| Protection of alpha(3) integrin-mediated podocyte shape by superoxide dismutase in the puromycin aminonucleoside nephrosis rat. | 2000 Jun |
|
| Caffeine augments proteinuria in puromycin-aminonucleoside nephrotic rats. | 2000 Mar |
|
| Cloning of rat nephrin: expression in developing glomeruli and in proteinuric states. | 2000 May |
|
| Increased synthesis and avp unresponsiveness of Na,K-ATPase in collecting duct from nephrotic rats. | 2001 Nov |
|
| GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis. A marker of acute podocyte injury. | 2002 Apr |
|
| Evaluation of the pituitary-testicular function during experimental nephrosis. | 2002 Apr 26 |
|
| Downregulation of vascular endothelial growth factor and its receptors in the kidney in rats with puromycin aminonucleoside nephrosis. | 2002 Jan |
|
| Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis. | 2002 Jan-Feb |
|
| Reduced 11beta-hydroxysteroid dehydrogenase activity in experimental nephrotic syndrome. | 2002 May |
|
| Identification by an EPR technique of decreased mitochondrial reducing activity in puromycin aminonucleoside-induced nephrosis. | 2002 Oct 15 |
|
| Soy protein diet ameliorates renal nitrotyrosine formation and chronic nephropathy induced by puromycin aminonucleoside. | 2004 Jan 9 |
|
| WT1-interacting protein and ZO-1 translocate into podocyte nuclei after puromycin aminonucleoside treatment. | 2005 Aug |
|
| Role of uroguanylin, a Peptide with natriuretic activity, in rats with experimental nephrotic syndrome. | 2005 Feb |
|
| Detection and localization of proteinuria by dynamic contrast-enhanced magnetic resonance imaging using MS325. | 2005 Jun |
|
| Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats. | 2005 Mar 7 |
Patents
Sample Use Guides
Rats were intravenously injected with puromycin aminonucleoside (75 mg/kg/day, dissolved in saline).
Route of Administration:
Intravenous
Conditionally immortalized human podocytes AB8/13 were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) (Life Technologies). The human podocytes proliferated at 33 C, with the addition of Insulin–Transferrin–Selenium (Life Technologies). After growing to 50–60% confluency, cells were transferred to 37 C for stopping proliferation and achieving full differentiation in 10–14 days. Fully differentiated human podocytes were treated with different reagents, such as PAN (Puromycin aminonucleoside), in RPMI 1640 medium plus 10% FBS at 37 C in a humidified atmosphere containing 5% CO2.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:55:40 GMT 2023
by
admin
on
Sat Dec 16 09:55:40 GMT 2023
|
| Record UNII |
0Q580U88V8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
58-60-6
Created by
admin on Sat Dec 16 09:55:40 GMT 2023 , Edited by admin on Sat Dec 16 09:55:40 GMT 2023
|
PRIMARY | |||
|
3056
Created by
admin on Sat Dec 16 09:55:40 GMT 2023 , Edited by admin on Sat Dec 16 09:55:40 GMT 2023
|
PRIMARY | |||
|
DTXSID7037264
Created by
admin on Sat Dec 16 09:55:40 GMT 2023 , Edited by admin on Sat Dec 16 09:55:40 GMT 2023
|
PRIMARY | |||
|
6020
Created by
admin on Sat Dec 16 09:55:40 GMT 2023 , Edited by admin on Sat Dec 16 09:55:40 GMT 2023
|
PRIMARY | |||
|
200-388-3
Created by
admin on Sat Dec 16 09:55:40 GMT 2023 , Edited by admin on Sat Dec 16 09:55:40 GMT 2023
|
PRIMARY | |||
|
42839
Created by
admin on Sat Dec 16 09:55:40 GMT 2023 , Edited by admin on Sat Dec 16 09:55:40 GMT 2023
|
PRIMARY | |||
|
0Q580U88V8
Created by
admin on Sat Dec 16 09:55:40 GMT 2023 , Edited by admin on Sat Dec 16 09:55:40 GMT 2023
|
PRIMARY |